Regulatory Compliance

Piscataway, N.J. – September 28, 2026 -- IEEE will host the 2026 IEEE Tech Summit: Ethical AI in Budapest, Hungary, on October 1-2, gathering researchers, policymakers, and industry executives to tackle algorithmic bias, AI regulation, and data privacy standards.

Summit targets governance gaps as AI adoption accelerates across industries

The two-day program, themed "Exploring Dimensions of Ethical AI in Technology," will feature keynotes, panel discussions, and breakout sessions on algorithmic fairness, AI policy, misinformation, and human-centered design. The event will also host the IEEE Tech Summit Ethical AI Global Founders Showcase and Awards, recognizing innovators building responsible AI systems.

Paris – September 28, 2026 -- ISO and the United Nations Development Programme (UNDP) have launched ISO/UNDP 53001, the world's first International Standard providing organizations with a requirements-based management system to integrate the Sustainable Development Goals (SDGs) into strategy, governance and operations.

Standard debuts at ISO Annual Meeting to close implementation gap on SDGs

The standard was unveiled on the opening day of the ISO Annual Meeting in Paris, marking a shift from voluntary SDG commitments to a structured, auditable framework. ISO/UNDP 53001 gives organizations tools to identify priorities, set objectives, embed them into existing processes and measure performance over time, offering a consistent basis to demonstrate compliance and strengthen accountability.

Hong Kong – September 28, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

Trial pits cadonilimab plus chemotherapy against nivolumab-based standard of care

The multicenter study compares cadonilimab combined with chemotherapy to chemotherapy with or without nivolumab in previously untreated, unresectable or metastatic G/GEJ patients. It is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, and Professors Jiafu Ji and Lin Shen of Peking University Cancer Hospital. Janjigian, Möhler and Shen were investigators on the earlier CheckMate 649 trial, which established nivolumab plus chemotherapy as a global first-line standard.

Wilmington, Del. – September 28, 2026 -- A new 51-jurisdiction dataset from Cuvo Health shows that only 14 states offer out-of-state physicians a telehealth registration or telemedicine license short of full licensure, exposing a costly compliance gap for digital health startups seeking national scale.

Virginia Beach – – September 26, 2026 -- Farm Aid 2026 drew a national spotlight to America's family farmers on Saturday, staged at Veterans United Home Loans Amphitheater as Chapter 12 farm bankruptcies rose 46% in 2025 and roughly 15,000 farms closed nationwide.

Chapter 12 farm bankruptcies climbed 46% in 2025, marking the third consecutive year of increases

The filing surge represents a sustained deterioration in farm finances rather than a single-year anomaly, with the closures translating into direct losses of local jobs, tax revenue and food-supply capacity across affected counties.

Irvine, Calif. – September 26, 2026 -- Sunwest Bank has acquired Nano Banc of Irvine, California, in an FDIC-assisted transaction that transfers approximately $605 million in deposits and $227 million in loans to the Sandy, Utah-based lender.

Regulators shut Nano Banc on September 25 before handing control to Sunwest

California's Department of Financial Protection and Innovation closed Nano Banc on Friday, September 25, placing it into FDIC receivership. The FDIC then entered an agreement with Sunwest Bank to acquire substantially all of Nano Banc's deposits and a portion of its assets, including the $605 million deposit book and $227 million loan portfolio.

Pune – – September 26, 2026 -- The global N95 mask market is projected to grow from $3.27 billion in 2025 to $11.08 billion by 2034, a 14.52% compound annual growth rate, according to Maximize Market Research.

North America dominates as major respirator makers expand capacity

North America held the largest regional share in 2025, driven by hospital demand, workplace safety mandates, and infection-control requirements. Manufacturers including 3M, Honeywell, Moldex-Metric, Cardinal Health, and Medline Industries maintain significant production presence in the region, supporting its lead position through continued investment in respiratory-protection capacity.

Pune, India – September 26, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pharmaceutical firms accelerate AI adoption to cut trial delays

Pharmaceutical and biotechnology companies, along with contract research organizations, hospitals and research institutes, are deploying machine learning, natural language processing and deep learning to speed patient screening, cohort selection, trial design and large-scale data analysis. These tools are applied across Phase I, Phase II and Phase III trials for patient recruitment, safety monitoring, drug discovery and personalized medicine.

Pune – September 26, 2026 -- The global clinical trials market reached USD 58.19 billion in 2025 and is forecast to grow at a 6.13% compound annual rate through 2034, reaching USD 99.4 billion, according to Maximize Market Research.

North America retains dominant share on trial infrastructure and R&D spend

North America leads global trial activity, underpinned by extensive pharmaceutical and biotechnology infrastructure, significant cancer research burden, and the presence of major contract research organizations. The United States drives the bulk of regional Phase I-IV trial volume, while Canada contributes through government investment in trial infrastructure. Europe holds a substantial share as well, with the UK, France, Germany, Italy, Spain, Sweden and Austria supporting research across oncology, cardiovascular disease, CNS conditions, diabetes, obesity and autoimmune disorders.

Pune, India – September 26, 2026 -- The global dietary supplements market was valued at USD 186.36 billion in 2025 and is forecast to reach USD 324.88 billion by 2034, expanding at a compound annual growth rate of 6.37% between 2026 and 2034, according to a new report from Maximize Market Research.

North America dominates supplement demand on preventive healthcare spending

North America leads the global market, driven by high consumer spending on health and wellness, strong preventive healthcare awareness, and regulatory clarity that supports major dietary supplement manufacturers. The United States remains the largest contributor within the region, with strong uptake of vitamins, minerals, herbal supplements, probiotics, and sports nutrition products.